Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael W Lark

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Arthritis and Rheumatism|May 15, 2003
Proteoglycan degradation after injurious compression of bovine and human articular cartilage in vitro: interaction with exogenous cytokinesParth Patwari, Michael N Cook, Michael A DiMicco, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 24, 2017
TRV0109101, a G Protein-Biased Agonist of the <i>µ</i>-Opioid Receptor, Does Not Promote Opioid-Induced Mechanical Allodynia following Chronic AdministrationMichael Koblish, Richard Carr, Edward R Siuda, et al.
Pain|June 24, 2014
Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteersDavid G Soergel, Ruth Ann Subach, Nancy Burnham, et al.
Arthritis and Rheumatism|October 1, 2009
Mechanical injury potentiates proteoglycan catabolism induced by interleukin-6 with soluble interleukin-6 receptor and tumor necrosis factor alpha in immature bovine and adult human articular cartilageYihong Sui, Jennifer H Lee, Michael A DiMicco, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 10, 2013
A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphineScott M DeWire, Dennis S Yamashita, David H Rominger, et al.
Molecular Pharmaceutics|April 19, 2005
An azepanone-based inhibitor of human cathepsin K with improved oral bioavailability in the rat and the monkeyRobert W Marquis, Keith W Ward, Theresa Roethke, et al.
Bone|May 9, 2002
A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized ratMichael W Lark, G B Stroup, I E James, et al.
Bioorganic & Medicinal Chemistry Letters|April 2, 2003
Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonistsWilliam H Miller, Peter J Manley, Russell D Cousins, et al.
Journal of Medicinal Chemistry|March 3, 2006
Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitorsDennis S Yamashita, Robert W Marquis, Ren Xie, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Arthritis and Rheumatism|May 15, 2003
Proteoglycan degradation after injurious compression of bovine and human articular cartilage in vitro: interaction with exogenous cytokinesParth Patwari, Michael N Cook, Michael A DiMicco, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 24, 2017
TRV0109101, a G Protein-Biased Agonist of the <i>µ</i>-Opioid Receptor, Does Not Promote Opioid-Induced Mechanical Allodynia following Chronic AdministrationMichael Koblish, Richard Carr, Edward R Siuda, et al.
Pain|June 24, 2014
Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteersDavid G Soergel, Ruth Ann Subach, Nancy Burnham, et al.
Arthritis and Rheumatism|October 1, 2009
Mechanical injury potentiates proteoglycan catabolism induced by interleukin-6 with soluble interleukin-6 receptor and tumor necrosis factor alpha in immature bovine and adult human articular cartilageYihong Sui, Jennifer H Lee, Michael A DiMicco, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 10, 2013
A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphineScott M DeWire, Dennis S Yamashita, David H Rominger, et al.
Molecular Pharmaceutics|April 19, 2005
An azepanone-based inhibitor of human cathepsin K with improved oral bioavailability in the rat and the monkeyRobert W Marquis, Keith W Ward, Theresa Roethke, et al.
Bone|May 9, 2002
A potent small molecule, nonpeptide inhibitor of cathepsin K (SB 331750) prevents bone matrix resorption in the ovariectomized ratMichael W Lark, G B Stroup, I E James, et al.
Bioorganic & Medicinal Chemistry Letters|April 2, 2003
Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin alphavbeta3) antagonistsWilliam H Miller, Peter J Manley, Russell D Cousins, et al.
Journal of Medicinal Chemistry|March 3, 2006
Structure activity relationships of 5-, 6-, and 7-methyl-substituted azepan-3-one cathepsin K inhibitorsDennis S Yamashita, Robert W Marquis, Ren Xie, et al.
Pageof 2